NanoVibronix, Inc. (NASDAQ: NAOV)

Introduction

NanoVibronix, Inc. ("NanoVibronix") is a medical device company headquartered in Elmsford, New York, with research and development operations in Nesher, Israel. The company utilizes proprietary low-intensity surface acoustic wave (SAW) technology to generate therapeutic ultrasound waves for applications such as pain management and infection prevention.

Corporate Structure

• Listing: NASDAQ (Ticker NAOV)
• Headquarters: Elmsford, New York; R&D in Nesher, Israel
• Employees: 11 – 50
• Executive Team:
  • Brian Murphy, Chief Executive Officer
  • Steve Brown, Chief Financial Officer
  • Lindsey Harrison, Vice President of Sales

Developments and News

• 2025-03-13: Reverse stock split announced (1 old share → 1/11 new share), effective 2025-03-14. The share price experienced a decline of approximately 10% in pre-market trading.
• 2025-05-16: Form 8-K filed detailing material agreements, asset dispositions, and corporate actions.
• 2025-05-19: Schedule 13G filed by Alpha Capital Anstalt, disclosing ownership of 82,471 shares (9.99% of common stock) as of 2025-04-29.
• 2025-05-20: Quarterly report on Form 10-Q filed for the period ended 2025-03-31.
• 2025-05-29 Trading Data:
  • Closing Price: $1.2598 (+47.24%)
  • Volume: 3,566,115 shares
  • 52-Week Range: $0.6669 – $16.25

Financial and Strategic Analysis

Metric	Value
Market Cap (intraday)	$2.21 M
Revenue (TTM)	$2.66 M
Net Income (TTM)	–$5.61 M
EPS (TTM)	–15.33
Profit Margin	–210.82%
Return on Assets (TTM)	–12.08%
Return on Equity (TTM)	–28.65%
Total Cash (MRQ)	$601 k
Debt/Equity (MRQ)	10.98%
Price/Sales (TTM)	0.12
Price/Book (MRQ)	0.06
Enterprise Value/Revenue	2.08
Beta (5Y Monthly)	2.04

Strategic Initiatives:

• Product Development: UroShield® is aimed at preventing catheter-associated infections, while PainShield® is an FDA-cleared patch designed for pain relief.
• Regulatory Pathways: Expected clinical and financial milestones with earnings scheduled between August 12 and August 18, 2025.
• Capital Requirements: The company has $601 k in cash, and negative levered free cash flow (–$998.75 k TTM) indicates ongoing funding needs.

Market Position and Industry Context

NanoVibronix operates within the medical equipment manufacturing sector, focusing on ultrasound-based therapies. Key areas of application include:

• Non-opioid pain management
• Prevention of catheter-related infections
• Opportunities for expansion into adjacent therapeutic segments

Valuation metrics (Price/Sales 0.12; Price/Book 0.06) suggest a discount relative to revenue and book value, while an enterprise value/revenue multiple of 2.08 indicates a market focus on potential future development rather than current earnings.

tl;dr

• Shares closed at $1.2598 on 2025-05-29, up 47.24% with 3.57 million shares traded.
• A 1-for-11 reverse stock split took effect on 2025-03-14; Form 8-K and Form 10-Q were filed in mid-May 2025.
• Alpha Capital Anstalt holds 9.99% of the common stock as of 2025-04-29.
• Upcoming events: Q2 earnings expected between August 12 and August 18, 2025; clinical and regulatory updates are anticipated.